Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 21, 2025
Event: Extension of the Company's stock buyback program.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data provided relates to the stock repurchase program:
- Total Authorization: $20,000,000 maximum value of common stock.
- Amount Repurchased to Date: $2,494,000 (as of May 21, 2025).
- Remaining Authorization: Approximately $17,506,000.
Material Changes
The Board of Directors authorized a one-year extension of the existing stock buyback program, which was set to expire in June 2025. The renewed program:
- Retains the same maximum value of $20,000,000 available for repurchase.
- Extends the expiration date to June 2026.
- Allows repurchases via open market transactions, privately negotiated transactions, or other methods compliant with Rule 10b-18.
Guidance, Outlook, and Risks
Management Commentary: The program does not obligate the Company to purchase any shares. The Board retains discretion to terminate, increase, or decrease the authorization at any time.
Risks/Contingencies: The filing does not disclose new risks or contingencies beyond the discretionary nature of the buyback program.
Key Facts for Investor Verification
- Verify the exact number of shares repurchased to date versus the dollar value ($2,494,000) to assess average repurchase price.
- Confirm the Company's current cash position to evaluate the capacity to utilize the remaining ~$17.5 million authorization.
- Monitor future 8-K filings for any updates on the actual execution of share repurchases under the extended program.